LIGAND PHARMACEUTICALS INCORPORATED Cash and Restricted Cash
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) had Cash and Restricted Cash of $1.01 billion as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-07
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.01B.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $115.09M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $174.93M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $139.38M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $1.01B 10-Q · filed 2026-08-07 |
| 2026-03-31 | $115.09M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $174.93M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $139.38M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $67.67M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $47.99M 10-Q · filed 2026-05-08 |
| 2024-12-31 | $72.31M 10-Q · filed 2026-08-07 |
| 2024-09-30 | $63.62M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $18.14M 10-Q · filed 2025-08-08 |
| 2024-03-31 | $50.09M 10-Q · filed 2025-05-09 |
| 2023-12-31 | $22.95M 10-K · filed 2026-02-27 |
| 2023-09-30 | $19.86M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $28.45M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $88.73M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $45.01M 10-K · filed 2026-02-27 |
| 2022-09-30 | $4.12M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $5.28M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $14.99M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $19.52M 10-K · filed 2025-02-28 |
| 2021-09-30 | $23.43M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $22.01M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $32.20M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $47.96M 10-K · filed 2024-02-29 |
| 2020-09-30 | $457.11M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $115.89M 10-Q · filed 2021-08-03 |
| 2020-03-31 | $118.26M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $72.27M 10-K · filed 2023-02-28 |
| 2019-09-30 | $226.31M 10-Q · filed 2020-11-06 |
| 2019-06-30 | $274.40M 10-Q · filed 2020-08-07 |
| 2019-03-31 | $107.37M 10-Q · filed 2020-05-08 |
| 2018-12-31 | $119.78M 10-K · filed 2022-02-28 |
| 2018-09-30 | $159.21M 10-Q · filed 2019-11-08 |
| 2018-06-30 | $151.46M 10-Q · filed 2019-08-08 |
| 2018-03-31 | $51.02M 10-Q · filed 2019-05-09 |
| 2017-12-31 | $20.62M 10-K · filed 2021-02-24 |
| 2017-09-30 | $32.74M 10-Q · filed 2018-11-08 |
| 2016-12-31 | $18.75M 10-K · filed 2020-02-27 |
| 2015-12-31 | $97.43M 10-K · filed 2019-02-28 |